乐普医疗：注射用重组A型肉毒毒素临床试验申请获批

Core Viewpoint - Lepu Medical (300003) announced that its subsidiary Lepu Jiantang has received approval from the National Medical Products Administration for the clinical trial of its self-developed injectable recombinant type A botulinum toxin [1] Group 1: Company Developments - The clinical trial application for the injectable recombinant type A botulinum toxin (LPJT-099/DP) has been approved [1] - The drug is indicated for the temporary improvement of moderate to severe frown lines caused by the activity of the corrugator and/or depressor anguli oris muscles in adults aged 65 and below [1]